Home › Funds › Duquesne Family Office LLC › NAMS

Duquesne Family Office LLC position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Duquesne Family Office LLC reported holding 3,357,146 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$81.6M, representing 2.17% of its reported portfolio and ranking #12 among its reported holdings. Duquesne Family Office LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)3.36M sh
Reported value held$81.65M
Portfolio Weight2.17%
First reportedQ3 2024
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Duquesne Family Office LLC's NAMS position evolved

Duquesne Family Office LLC first disclosed a stake in NAMS in Q3 2024 at 287,535 shares (US$4.8M). The position peaked in Q4 2025 at 3,070,146 shares, worth US$107.7M. Across 9 filings, Duquesne Family Office LLC increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 3,357,146 shares valued at US$81.6M — an increase of 287,000 shares quarter over quarter.. Notable position changes include a 178% increase in Q1 2025 (shares fell 8% over the following quarter), a 131% increase in Q3 2025 (shares rose 23% over the following quarter), a 60% increase in Q4 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 287.54K $4.77M New
Q4 2024 287.54K $7.39M Hold
Q1 2025 800.36K $16.38M Add
Q2 2025 832.17K $15.07M Add
Q3 2025 1.92M $54.71M Add
Q4 2025 3.07M $107.70M Add
Q1 2026 3.07M $98.28M Hold
Q2 2026 3.07M $104.05M Hold
Q3 2026 3.36M $81.65M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 34 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Duquesne Family Office LLC held NAMS?

Duquesne Family Office LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Duquesne Family Office LLC's current position in NAMS?

As of Q3 2026, Duquesne Family Office LLC holds 3.36M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $81.65M, representing 2.17% of its reported portfolio and ranking #12.

Has Duquesne Family Office LLC been buying or selling NAMS?

In the latest 13F filing (Q3 2026), Duquesne Family Office LLC increased its position in NAMS. The position peaked in Q4 2025 at 3.07M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.